A new PCT patent application claiming new viral protein E7 degraders has been published as WO2022219157A1. The invention was made […]
Anixa-MolGenie compounds are more potent than the protease inhibitor in Pfizer’s PAXLOVID™ at inhibiting the main protease of SARS-CoV-2
SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused […]
Good news for small molecule SARS-CoV-2 virus inhibitors: Pfizer demonstrates clinical efficacy!
Great news for researchers like us that are working on drug candidates to treat SARS-CoV-2 infections. Pfizer could demonstrate that […]
Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta Variant
While vaccination has proven to be an effective strategy to prevent Covid-19, the need exists for inexpensive, room-temperature stable, and […]